Physician profile
Halis Sonmez
NPI 1578792834
$4,777.56
in general payments reported to CMS, 2019-2025
28 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $251 · 2021: $671 · 2022: $688 · 2023: $323 · 2024: $1,177 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amneal Pharmaceuticals LLC | $663.87 | 2022-2025 | Unithroid |
| Amgen INC. | $630.87 | 2021-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $566.07 | 2021-2024 | |
| Abbott Laboratories | $394.81 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $378.83 | 2019-2020 | |
| Radius Health, INC. | $244.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $160.44 | 2019-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $148.62 | 2023-2024 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.36 | 2019-2022 | |
| Lilly USA, LLC | $127.99 | 2019-2024 | Mounjaro |
| Ascendis Pharma Endocrinology INC | $120.42 | 2023-2025 | Yorvipath |
| Amarin Pharma, INC. | $109.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $56.82 | 2020-2021 | |
| Insulet Corporation | $49.02 | 2025 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.77 | 2019-2021 | |
| Dynavax Technologies Corporation | $40.68 | 2020-2023 | Heplisav-B |
| Exact Sciences Corporation | $34.21 | 2024 | Cologuard Collection Kit |
| Tandem Diabetes Care, INC. | $27.93 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ironwood Pharmaceuticals, INC | $25.00 | 2024 | |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Ardelyx, INC. | $20.99 | 2022 | |
| Corcept Therapeutics | $18.58 | 2024 | Korlym |
| Dexcom, INC. | $16.63 | 2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $15.84 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Micro-Tech Endoscopy USA, INC. | $15.56 | 2024 | Blueboost |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halis Sonmez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.